146 related articles for article (PubMed ID: 38047833)
1. Repurposing of Tuberculosis Drug Candidates for the Treatment of Mycobacterium ulcerans Disease.
Warryn L; Pluschke G
Chimia (Aarau); 2023 Sep; 77(9):577-581. PubMed ID: 38047833
[TBL] [Abstract][Full Text] [Related]
2. Targeting the Mycobacterium ulcerans cytochrome bc
Scherr N; Bieri R; Thomas SS; Chauffour A; Kalia NP; Schneide P; Ruf MT; Lamelas A; Manimekalai MSS; Grüber G; Ishii N; Suzuki K; Tanner M; Moraski GC; Miller MJ; Witschel M; Jarlier V; Pluschke G; Pethe K
Nat Commun; 2018 Dec; 9(1):5370. PubMed ID: 30560872
[TBL] [Abstract][Full Text] [Related]
3. Shortening Buruli Ulcer Treatment with Combination Therapy Targeting the Respiratory Chain and Exploiting Mycobacterium ulcerans Gene Decay.
Converse PJ; Almeida DV; Tyagi S; Xu J; Nuermberger EL
Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31036687
[TBL] [Abstract][Full Text] [Related]
4. Toward a Single-Dose Cure for Buruli Ulcer.
Thomas SS; Kalia NP; Ruf MT; Pluschke G; Pethe K
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32631818
[TBL] [Abstract][Full Text] [Related]
5. Telacebec (Q203)-containing intermittent oral regimens sterilized mice infected with Mycobacterium ulcerans after only 16 doses.
Chauffour A; Robert J; Veziris N; Aubry A; Pethe K; Jarlier V
PLoS Negl Trop Dis; 2020 Aug; 14(8):e0007857. PubMed ID: 32866170
[TBL] [Abstract][Full Text] [Related]
6. Drugs for treating Buruli ulcer (Mycobacterium ulcerans disease).
Yotsu RR; Richardson M; Ishii N
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012118. PubMed ID: 30136733
[TBL] [Abstract][Full Text] [Related]
7. Pharmacologic management of
Van Der Werf TS; Barogui YT; Converse PJ; Phillips RO; Stienstra Y
Expert Rev Clin Pharmacol; 2020 Apr; 13(4):391-401. PubMed ID: 32310683
[TBL] [Abstract][Full Text] [Related]
8.
Kwofie SK; Dankwa B; Odame EA; Agamah FE; Doe LPA; Teye J; Agyapong O; Miller WA; Mosi L; Wilson MD
Molecules; 2018 Jun; 23(7):. PubMed ID: 29954088
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of rifampicin-streptomycin for treatment of Buruli ulcer: a systematic review.
Tanywe A; Fernandez RS
JBI Database System Rev Implement Rep; 2017 Jan; 15(1):119-139. PubMed ID: 28085731
[TBL] [Abstract][Full Text] [Related]
10. Impact of Dose, Duration, and Immune Status on Efficacy of Ultrashort Telacebec Regimens in Mouse Models of Buruli Ulcer.
Komm O; Almeida DV; Converse PJ; Omansen TF; Nuermberger EL
Antimicrob Agents Chemother; 2021 Oct; 65(11):e0141821. PubMed ID: 34460302
[TBL] [Abstract][Full Text] [Related]
11. High-Dose Rifamycins Enable Shorter Oral Treatment in a Murine Model of Mycobacterium ulcerans Disease.
Omansen TF; Almeida D; Converse PJ; Li SY; Lee J; Stienstra Y; van der Werf T; Grosset JH; Nuermberger EL
Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30455239
[TBL] [Abstract][Full Text] [Related]
12. In-vitro activity of avermectins against Mycobacterium ulcerans.
Omansen TF; Porter JL; Johnson PD; van der Werf TS; Stienstra Y; Stinear TP
PLoS Negl Trop Dis; 2015 Mar; 9(3):e0003549. PubMed ID: 25742173
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy-associated changes of histopathological features of Mycobacterium ulcerans lesions in a Buruli ulcer mouse model.
Ruf MT; Schütte D; Chauffour A; Jarlier V; Ji B; Pluschke G
Antimicrob Agents Chemother; 2012 Feb; 56(2):687-96. PubMed ID: 22143518
[TBL] [Abstract][Full Text] [Related]
14. Rapid, serial, non-invasive assessment of drug efficacy in mice with autoluminescent Mycobacterium ulcerans infection.
Zhang T; Li SY; Converse PJ; Grosset JH; Nuermberger EL
PLoS Negl Trop Dis; 2013; 7(12):e2598. PubMed ID: 24367713
[TBL] [Abstract][Full Text] [Related]
15. Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial.
Nienhuis WA; Stienstra Y; Thompson WA; Awuah PC; Abass KM; Tuah W; Awua-Boateng NY; Ampadu EO; Siegmund V; Schouten JP; Adjei O; Bretzel G; van der Werf TS
Lancet; 2010 Feb; 375(9715):664-72. PubMed ID: 20137805
[TBL] [Abstract][Full Text] [Related]
16. Telacebec for Ultrashort Treatment of Buruli Ulcer in a Mouse Model.
Almeida DV; Converse PJ; Omansen TF; Tyagi S; Tasneen R; Kim J; Nuermberger EL
Antimicrob Agents Chemother; 2020 May; 64(6):. PubMed ID: 32205344
[TBL] [Abstract][Full Text] [Related]
17. Treating Mycobacterium ulcerans disease (Buruli ulcer): from surgery to antibiotics, is the pill mightier than the knife?
Converse PJ; Nuermberger EL; Almeida DV; Grosset JH
Future Microbiol; 2011 Oct; 6(10):1185-98. PubMed ID: 22004037
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic efficacy of rifalazil (KRM-1648) in a M. ulcerans-induced Buruli ulcer mouse model.
Fukano H; Nakanaga K; Goto M; Yoshida M; Ishii N; Hoshino Y
PLoS One; 2022; 17(10):e0274742. PubMed ID: 36201529
[TBL] [Abstract][Full Text] [Related]
19. Successful outcomes with oral fluoroquinolones combined with rifampicin in the treatment of Mycobacterium ulcerans: an observational cohort study.
O'Brien DP; McDonald A; Callan P; Robson M; Friedman ND; Hughes A; Holten I; Walton A; Athan E
PLoS Negl Trop Dis; 2012 Jan; 6(1):e1473. PubMed ID: 22272368
[TBL] [Abstract][Full Text] [Related]
20. Clearance of viable Mycobacterium ulcerans from Buruli ulcer lesions during antibiotic treatment as determined by combined 16S rRNA reverse transcriptase /IS 2404 qPCR assay.
Sarpong-Duah M; Frimpong M; Beissner M; Saar M; Laing K; Sarpong F; Loglo AD; Abass KM; Frempong M; Sarfo FS; Bretzel G; Wansbrough-Jones M; Phillips RO
PLoS Negl Trop Dis; 2017 Jul; 11(7):e0005695. PubMed ID: 28671942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
